Breakthrough discovery will change treatment for Chronic Obstructive Pulmonary Disease

Dr. Louise Hackett’s research will introduce better treatment for Chronic Obstructive Pulmonary Disease

Our lungs constitute a major part in our respiratory system. However, due to smoking and various other factors, many of us have lung diseases, and Chronic Obstructive Pulmonary Disease is also one of those lung disorders, affecting lots of people.

Dr. Tillie-Louise Hackett has started her research on Chronic Obstructive Pulmonary Disease that is also known as COPD. This COPD has already snatched the lives of several people. This is a progressive or chronic disease, which can damage the lung tissue very slowly. With her dedicated study, Hackett is trying to find out how the normal healing process of our lungs is getting disrupted. She also strives to know how it causes inflammation issue and brings about a transformation to our lung tissues.

At present, the patients, having mild symptoms, diagnosed through lung test, do not go through much intricate treatment. Since their symptoms are very mild, the physicians believe that they have no damage to the lungs. However, Hackett has realized that it is essential to know the damage level, and her team tries to make out the condition in advance to give the best result to the patients.

What is Hackett’s aim behind her research? 

The major intention of Hackett is to find out everything of the airways’ micro-environment. The researchers have made the effort to know the factor, causing fibrosis in the airways. They think that it will surely avert the adverse condition, resulting in the disruptive airway issues, like Chronic Obstructive Pulmonary Diseaseand asthma. Thus, the researchers are trying to learn more of COPD to make out the process in which our lungs and airways are affected for illnesses. Their increasing knowledge on this disease will surely help them to offer better treatment to everyone.

In the disease, like Chronic Obstructive Pulmonary Disease, we have found lesions production due to the continuous injury at the time of inhalation. The exposure to smoke inflicts this injury. However, the real mechanism behind it is not known clearly. The researchers, including Dr. Hackett have recently dealt with silico drug screening process. They have detected Gly-His-Lys as one of the lung cells destruction modulators.

Dr. Hackett wants to undergo pre clinical research process for the assessment of to evaluate GHK, the potential Chronic Obstructive Pulmonary Disease treatment. Her target is to get the FDA approval by introducing a new, effective drug.

The application of new technology for Chronic Obstructive Pulmonary Diseasetherapy-

To make out the COPD determinants, the researchers, at first, applies the innovative micro x-ray process, one of the computed imaging technologies. These technologies are intended for finding out the effect on airways of COPD patients.

In addition to it, Dr. Hackett has also worked on lung cells, by deriving them from COPD patients. She is going to detect the primary ones of all the cells, present in the airway blockage. She is also interested to know whether GHK is capable of modifying the damaged or affected cells. Her thorough research will help us to realize if this GHK is effective as the therapeutic solutions.

Thus, Dr. Hackett’s research will raise hope among all Chronic Obstructive Pulmonary Disease patients in this world.